Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Pharma Acquires Dynogen Research Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Astellas Pharma Acquires Dynogen Research Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Astellas Pharma has acquired Dynogen Pharmaceuticals NC-based research facility. The research facility specializes in state-of-the-art preclinical studies for genitourinary disorders. Financial details were not disclosed.

“We’ve built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive in-licensing program,” said Lee R. Brettman, M.D., president and chief executive officer of Dynogen. “We’ve maximized the value of the North Carolina facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs.”

“Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition of this research facility will strengthen our capabilities in this key area,” said Isao Yanagisawa, Ph.D., senior corporate officer of Astellas Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters